Mount Sinai Medical Center of Florida, Inc.

Procedure reduces recovery period, pain, and post-surgery complications and improves outcomes, according to new article published by the official journal of the American Orthopaedic Foot & Ankle Society. MIAMI, Sept. 10, 2024 /PRNewswire/ -- Led by Dr. Vulcano, Chief of Orthopedic Surgery at Mount Sinai Medical Center, a new study explores a minimally invasive procedure to treat a common foot and ankle ailment (Achilles tendinopathy) by analyzing patient-reported outcomes with a minimum two-year patient follow-up. The keyhole procedure, dubbed a percutaneous Zadek osteotomy (ZO), is a minimally invasive technique that can significantly decrease pain and provide patient with relief in as little as six weeks. Traditional open surgical approaches can take as long as one year for full recovery. First-line treatment includes conservative therapies such as anti-inflammatory medications, activity limitation, physical therapy, and shoe wear modification. Eccentric loading therapy and shockwave therapy have demonstrated some success in this patient population. However, these non-operative strategies fail in over 80% of cases, and surgical intervention is considered more effective. Dr. Vulcano's study has demonstrated an extremely high patient satisfaction and very low complication rate, with recovery times often thought unthinkable with a traditional surgery. While Dr. Vulcano has treated Olympians and other professional athletes, he says that most people who suffer from Achilles tendinopathy are non-athletic women in their 40's and men in their 60's. He is one of a handful of doctors in the country to revolutionize the minimally invasive approach, which includes making two tiny incisions in the heel and removing a 10mm wedge of bone. This alters the orientation of the tendon fibers and optimizes its biomechanics. "As a result of cutting-edge technology and the latest techniques at Mount Sinai, patients experience reduced postoperative pain and quicker return to function," explains Dr. Vulcano. "This is particularly important to athletes who can return to working out within weeks of surgery compared to traditional Achilles surgery." About Mount Sinai Medical Center Founded in 1949, Mount Sinai Medical Center is the largest independent, private, not-for-profit teaching hospital in South Florida. Mount Sinai's mission is to provide quality health care to a diverse community enhanced through teaching, research, charity care, and financial responsibility. Mount Sinai's Centers of Excellence combine technology, research, and academics to provide innovative and comprehensive care in cardiology, neuroscience, oncology, urology, and orthopedics. One of the original statutory teaching hospitals in the state of Florida, Mount Sinai is the hospital of choice for those who seek the level of expertise and care that only a teaching hospital can offer. Mount Sinai currently offers nine convenient locations in Miami-Dade County, including three emergency centers, and two specialty care offices and a primary care office in Monroe County. For more information on Mount Sinai Medical Center, visit msmc.com or call 305.674.CARE (2273). Media Contact: Erica Corsano [email protected] 617.510.1825 SOURCE Mount Sinai Medical Center of Florida

SandboxAQ developed AI-enhanced magnetocardiography (MCG) technology that offers a non-invasive, radiation-free cardiac assessment and aims to help clinicians make a faster, more accurate diagnosis. Mayo Clinic is partnering with startup SandboxAQ to study a new medical device that uses quantum sensing technology and advanced AI algorithms for rapid diagnosis in cardiac care, such as potentially detecting a heart attack.SandboxAQ was spun out of Alphabet in 2022 and is working on solutions at the nexus of AI and quantum technology, with a particular focus on cybersecurity, navigation, sensing technology, which is where its medical devices fall, and also using large quantitative models to aid drug discovery and materials science."The A and the Q stand for AI and quantum but what we're really good at is delivering these deep tech to solve impactful problems in different industries," said Kit Yee Au-Yeung, Ph.D., general manager of the sensing division at SandboxAQ, in an exclusive interview with Fierce Healthcare.She points out that the startup's work in healthcare is different from other efforts to use large language models (LLMs) or generative AI. "We're focused on a physics-informed application of AI to extract useful information," she said.A biomedical engineer by background, Au-Yeung has worked in the medical devices field for 20 years and she was part of the founding team of iRhythm Technologies. She joined Google X, the moonshot factory, in 2018 before joining SandboxAQ. Her 16-person team is made up of physicists and engineers working to build a diagnostic device to impact cardiac care. Au-Yeung's team developed AI-enhanced magnetocardiography (MCG) technology that offers a non-invasive, radiation-free cardiac assessment and aims to help clinicians make a faster, more accurate diagnosis. To guide its work, SandboxAQ put together a clinical advisory board, which includes Toby Cosgrove, M.D., cardiac surgeon and former president and CEO of the Cleveland Clinic for 13 years. Faster diagnosis can improve patient care and reduce the economic burden of medical care, according to a study from the American Heart Association.Chest pain represents nearly 5% of all the reasons prompting patients to seek care in the ED, amounting to an estimated 6.5 million encounters in the United States in 2017. And, it's a condition frequently hospitalized. It's estimated that as much as $3 billion of national health care expenditures could be avoided annually by narrowing the variation in ED hospitalizations for chest pain.The non-contact cardiac imaging device uses magnetic sensors and advanced AI algorithms can produce a rapid visualization and assessment of the magnetic signals of the heart. The Mayo Clinic is working with SandboxAQ on a clinical research study to examine the relationship between MCG and the findings seen in angiography. The study, which will involve about 150 patients, will take place throughout 2024 and 2025 at the Mayo Clinic in Rochester, Minnesota, the organizations said."We partner with prestigious institutions like the Mayo Clinic because we believe in their research rigor. We're good at the AI and engineering and the physics and Mayo Clinic brings an expertise in clinical practice and understanding the gaps in clinical service. We really want to take this technology out of the research lab and into a clinicians' work," Au-Yeung said.The startup's novel MCG imaging system, called CardiAQ, is still in research and development as an investigation device but Au-Yeung sees the potential for the technology to overcome many of the existing tools used by cardiologists to make heart health decisions.SandboxAQ completed a feasibility study with the University of California at San Francisco (UCSF) Medical Center, and have ongoing studies at Mount Sinai Medical Center in New York City to test MCG’s ability to improve cardiac diagnosis.The startup eventually wants to pursue regulatory clearance through the FDA for its medical device. "My vision is that we know enough about our technology and can be ready for something like a pivotal study in 2025 and that study would last between nine to 12 months and then that will go into an FDA submission and clearance," she said."Magnetocardiography as a concept dates back to 1960s, so we're not the first group to do that. But how we're different is that we use a new approach to do that," Au-Yeung said.Widespread adoption of MCG technology has been a challenge. Historically, MCG systems required large dedicated rooms and expensive maintenance and came with a large price tag, according to the company."Previous generations of MCG to get this data requires really big machinery, couple million dollars; you will have to construct a room to shield out all the magnetic noise. around the area in order to be able to capture heart signal. My team's approach is different. We want the device to go to the patient as opposed to asking the patient to go to the device. We want it to be a bedside tool," she said."We leverage high-performance sensors, like quantum sensors, so that we can capture this tiny signal and we use AI to do noise rejection, to learn the environment, so that we can separate out what's coming from the heart and what's coming out from the environment. That's what enables us to build something that can be used anywhere. That's the goal," she added. Au-Yeung and her team see the potential to improve how clinicians approach cardiac diagnostics and patient care. The standard diagnostic tool currently used to monitor heart activity and detect cardiac issues is the electrocardiogram (EKG), a 150-year-old technology that has vastly improved cardiac care.But, EKG tech has limitations. When measured by EKG, the electrical signals of the heart may be distorted as they pass through the body. This can complicate diagnosis and can lead to inaccurate and potentially dangerous conclusions, according to SandboxAQ executives. Biomarker tests also are often used."These tools are good, but they are suboptimal because of their sensitivity and specificity performance. A lot of patients fall into a gray zone, even when you have these results. A patient's physician will decide they don't have enough information so they decide to keep the patient for observation and have to admit them to the hospital to do additional testing and that becomes very costly," Au-Yeung said."The first application that we are going after is heart attack triage in the emergency department. Magnetocardiography has been proposed to be a frontline tool, added to the toolbox of physicians to make this decision much faster and more accurately," she said, adding, "This is just our first application. There are other indications that we will be researching in the future."CardiAQ detects the magnetic fields of the heart using room-temperature sensors and AI software in a process. The device does not need any room shielding which significantly opens up the use cases from ER, to bedside and even in ambulances."Cardiovascular disease is the number one killer across most of the world.  As a doctor, having the most accurate and timely information about a patient’s cardiac state is critical for making life-saving treatment decisions,” Cosgrove said in a statement. “SandboxAQ's CardiAQ device shows how AI and this next generation of sensing technologies have the potential to revolutionize cardiac diagnosis and address the unmet clinical need for more effective patient care. This is the future of medicine.” Novel methods to easily and accurately diagnose disease are urgently needed, Au-Yeung said. "CardiAQ captures detailed data from the heart, which could lead to faster, more accurate diagnoses and fill in the gap between low-cost EKG or biomarker tests and high-cost CT scans or invasive angiography.”Some of the benefits of the CardiAQ device include non-invasive, radiation-free cardiac assessment, the potential for earlier detection of cardiac issues, improved accessibility of advanced cardiac diagnostics and AI-driven analysis for more accurate and rapid diagnosis, according to the company. “The current methods for heart attack diagnosis can miss many cardiac conditions. Blood tests are costly, take time to process, and may give false negatives and positives. SandboxAQ’s goal is to revolutionize cardiac diagnoses with contactless, high-performance sensors and sophisticated AI that has the potential to benefit patients, save lives, and impact cardiac care globally with on-demand, real-time analysis," said Jeffrey Bander, M.D., Chief of Cardiology at Mount Sinai West.The company is part of a wave of AI-based startups making inroads in healthcare, which is poised to be a lucrative market for AI. The AI-enhanced diagnostic market is set to grow from $16.3 billion in 2023 to $71.2 billion in 2027. In 2023, SandboxAQ raised $500 million to fuel its product development in AI and quantum computing.

The partnership launches full-service RPM and CCM for chronic condition management with plans to expand across 13 Mount Sinai locations and serve up to 10,000 patients across South Florida. MIAMI, June 11, 2024 /PRNewswire/ -- HealthSnap, a leading virtual care management platform, and Mount Sinai Medical Center, the largest private, independent not-for-profit teaching hospital in Florida, today announced a new Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) partnership. The partnership launched in March 2024 with Remote Patient Monitoring, and is currently live at three Mount Sinai locations, with plans to expand to 13 South Florida locations by year-end. Continue Reading The partnership launches full-service RPM and CCM for chronic condition management with plans to expand across 13 Mount Sinai locations and serve up to 10,000 patients across South Florida. With this partnership, Mount Sinai plans to continue expanding their in-house CCM program to bring the service offering to their Medicare patient population at scale. The CCM partnership is anticipated to go live in July across Mount Sinai Primary Care. Both the RPM and CCM programs are expected to support more than 4,000 patient lives by the end of this year, with plans to reach up to 10,000 patients living with chronic conditions over time. "Mount Sinai Primary Care is committed to delivering care that is accessible, comprehensive, and evidence-based, with a patient-centric approach," said Dr. Clifford Medina, MD, Chief of General Medicine at Mount Sinai Medical Center. "HealthSnap's extensive clinical resources, innovative platform, and proven patient outcomes enable us to provide proactive chronic condition care at scale across our entire primary care patient population." HealthSnap is powering a new paradigm in chronic condition management, enabling care teams to proactively manage such conditions, helping patients stay connected to their care teams between clinic visits, and significantly improving patient outcomes. Mount Sinai's new HealthSnap-powered RPM and CCM programs will support patients with hypertension, diabetes, congestive heart failure, COPD, asthma, obesity, and osteoporosis, with plans to extend support to additional conditions and acuities in the future. At present, EPIC integration has already been completed, providing Mount Sinai clinicians with a centralized platform to gather, analyze, and act on patient data, as well as to efficiently file claims. "We designed HealthSnap as a fully integrated virtual care management platform that is able to serve the largest health systems in the nation – from clinical resources to HITRUST certification to EPIC integration, it is a priority for us to remove the friction from scaling RPM & CCM programs that can benefit so many people living with chronic conditions," said Samson Magid, Co-Founder & CEO of HealthSnap. "Mount Sinai is a great example of an organization that serves a diverse patient population with multiple locations across the state, and we are looking forward to growing our partnership." ABOUT MOUNT SINAI MEDICAL CENTER Founded in 1949, Mount Sinai Medical Center is the largest independent, private, not-for-profit teaching hospital in South Florida. Mount Sinai's mission is to provide quality health care to a diverse community enhanced through teaching, research, charity care, and financial responsibility. Mount Sinai's Centers of Excellence combine technology, research, and academics to provide innovative and comprehensive care in cardiology, neuroscience, oncology, urology, and orthopedics. One of the original statutory teaching hospitals in the state of Florida, Mount Sinai is the hospital of choice for those who seek the level of expertise and care that only a teaching hospital can offer. Mount Sinai currently offers nine convenient locations in Miami-Dade County, including three emergency centers, and three specialty care offices and a primary care office in Monroe County. For more information on Mount Sinai Medical Center, visit msmc.com or call 305.674.CARE (2273). ABOUT HEALTHSNAP HealthSnap is an integrated virtual care management platform that helps healthcare organizations improve patient outcomes, reduce utilization, and diversify revenue streams. From chronic disease-agnostic Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) to AI-guided care coordination, virtual care delivery, patented billing tools, population analytics – and so much more, HealthSnap is the simplest way to manage chronic conditions remotely. Visit or follow us on LinkedIn for more information. HealthSnap Media Contact: Sunny Ghia [email protected] (888) 780-1872 Ext. 701 SOURCE HealthSnap